Cointime

Anokion

company

About

Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.

  • 1 - 10

Highlights

Total Funding Amount
$77.50M
Funding Rounds
2
Investors
1
Investments
1

Details

Last Funding Type
Series B
Last Funding Money Raised
$40M
Industries
Biotechnology,Clinical Trials,Therapeutics
Founded date
Jan 1, 2010
Number Of Employee
1 - 10
Operating Status
Active

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$77.50M
Anokion has raised a total of $77.50M in funding over 2 rounds. Their latest funding was raised on Sep 11, 2019 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 11, 2019 Series B $40M 1 — — Detail
May 9, 2014 Series A $37.50M 1 Versant Ventures — Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Anokion has made 1 investments. Their most recent investment was on Sep 14, 2022, when Arpeggi raised $5.10M.
Date Company Name
Round Money Raised Industry Lead Investor
Sep 14, 2022 Arpeggi
Seed $5.10M Blockchain —

Investors

Number of Lead Investors
Number of Investors
1
1
Anokion is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures — Series B
Cointime
Содержание
компания